Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.
- DOI
- 10.1111/dom.70520
- Published
- 2026 Apr
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.70520,
title = {Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.},
author = {Nardone M and Moedt E and Heerspink HJL and Davies MJ and Girard M and Cherney DZI and Muskiet MHA},
year = {2026},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.70520},
url = {https://doi.org/10.1111/dom.70520}
}RIS
TY - JOUR TI - Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial. AU - Nardone M AU - Moedt E AU - Heerspink HJL AU - Davies MJ AU - Girard M AU - Cherney DZI AU - Muskiet MHA PY - 2026 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.70520 UR - https://doi.org/10.1111/dom.70520 ER -
APA
M, N., E, M., HJL, H., MJ, D., M, G., DZI, C., & MHA, M. (2026). Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70520
Source records
- pubmed · retrieved 2026-09-26T19:30:34.150Z